Table 1 Clinico-pathological characteristics of the included 100 patients
Item | Value | Percentage |
|---|---|---|
Age (median) | 33 (15–74) years | |
Gender | Male: female | 37%: 63% |
HB level | ≥ 10.5 g/dl | 64% |
< 10.5 g/dl | 36% | |
WBC | ≥ 15 × 109/l | 15% |
< 15 × 109/l | 85% | |
Serum albumin | <4 g/dl | 35% |
≥4 g/dl | 65% | |
HCV antibodies | Positive | 14% |
Negative | 86% | |
Performance status | <2 | 95% |
≥2 | 5% | |
B symptoms | Absent | 46% |
Present | 54% | |
Bulky disease | No | 89% |
Yes | 11% | |
Histopathology subtype | Mixed cellularity | 46% |
Nodular sclerosis | 42% | |
Lymphocyte rich | 12% | |
Extra nodal disease | No | 73% |
Yes | 27% | |
Spleen involvement | No | 78% |
Yes | 22% | |
Bone marrow involvement | No | 96% |
Yes | 4% | |
Ann Arbor stage | I | 1% |
II | 27% | |
III | 42% | |
IV | 30% | |
Stage | Limited | 21% |
Advanced | 79% | |
IPS | < 3 | 60% |
≥ 3 | 40% | |
CD 68 | I | 41% |
II | 41% | |
III | 18% | |
CD 163 | I | 37% |
II | 40% | |
III | 23% | |
Response | CR | 61% |
PR | 12% | |
PD | 7% | |
SD | 20% | |
Relapse after CR | Yes:no | 20%:41% |
Status | Alive:dead | 82%:18% |